Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.

Published in: European journal of clinical pharmacology (2023)

Outpatients prescribed fluvoxamine around the time of COVID-19 diagnosis were not at a reduced risk of hospitalizations and mortality compared to their non-prescribed peers.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
cardiovascular disease
type diabetes
risk factors